NetworkNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and peptide chemist with more than 20 years of experience, 17 issued patents and more than 50 publications, Adaptogenics also intends to pursue research programs focused initially on mitochondrial biology and the resolution of inflammation, with the goal of developing proprietary assets supported by measurable scientific outcomes, defined development milestones and meaningful intellectual property.
To view the full article, visit https://nnw.fm/Pht00
NOTE TO INVESTORS: The latest news and updates relating to ADPTare available in the company’s newsroom at https://nnw.fm/ADPT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and peptide chemist with more than 20 years of experience, 17 issued patents and more than 50 publications, Adaptogenics also intends to pursue research programs focused initially on mitochondrial biology and the resolution of inflammation, with the goal of developing proprietary assets supported by measurable scientific outcomes, defined development milestones and meaningful intellectual property.
To view the full article, visit https://nnw.fm/Pht00
NOTE TO INVESTORS: The latest news and updates relating to ADPTare available in the company’s newsroom at https://nnw.fm/ADPT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
